EORA-213

EORA-213 is a proprietary small molecule therapeutic candidate being developed by Eolas Therapeutics for the treatment of alcohol-use disorder (AUD). Currently in Phase 1 clinical development, the program is part of Eolas's specialized pipeline targeting substance use disorders. While the specific molecular target for EORA-213 has not been publicly disclosed in the company's high-level pipeline, Eolas Therapeutics' research focus centers on neurobiological mechanisms of addiction, particularly the orexin system, to address craving and prevent relapse. The drug represents a key asset in the company's efforts to provide novel pharmacological interventions for addiction management.